title: Integrilin, Intervention, and the Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy Trial.
abstract: Eptifibatide (Integrelin, Corr Therapeutics, South San Francisco, CA) is a cyclic heptapeptide competitive inhibitor of the platelet glycoprotein (GP) IIb/IIIa receptor that has a short half-life. The results of the initial dose-finding and phase III trials are reviewed and the ongoing Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT) trial are described.
authors.affiliation: Division of Cardiology, National Naval Medical Center, 8901 Wisconsin Avenue, Bethesda, MD 20889, USA.
authors.initials: MC
authors.lastname: Thel